HemaSphere (Jun 2022)
P378: THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL
- Y. Wang,
- X. Hu,
- D. Zhang,
- Q. Gao,
- X. Zhai,
- H. Wang,
- Y. Gao,
- Y. Miao,
- Y. Guo,
- W. Zhang,
- X. Ru,
- X. Li,
- F. Guan
Affiliations
- Y. Wang
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- X. Hu
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- D. Zhang
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- Q. Gao
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- X. Zhai
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- H. Wang
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- Y. Gao
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- Y. Miao
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- Y. Guo
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- W. Zhang
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- X. Ru
- 1 Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’An
- X. Li
- 2 School of Medicine, Northwest University, Xi’An, China
- F. Guan
- 2 School of Medicine, Northwest University, Xi’An, China
- DOI
- https://doi.org/10.1097/01.HS9.0000844400.72191.2e
- Journal volume & issue
-
Vol. 6
pp. 278 – 279
Abstract
No abstracts available.